396 related articles for article (PubMed ID: 26213859)
21. Adipose tissue depot-specific differences in the regulation of hyaluronan production of relevance to Graves' orbitopathy.
Zhang L; Grennan-Jones F; Lane C; Rees DA; Dayan CM; Ludgate M
J Clin Endocrinol Metab; 2012 Feb; 97(2):653-62. PubMed ID: 22162480
[TBL] [Abstract][Full Text] [Related]
22. Thyrotropin receptor-stimulating Graves' disease immunoglobulins induce hyaluronan synthesis by differentiated orbital fibroblasts from patients with Graves' ophthalmopathy not only via cyclic adenosine monophosphate signaling pathways.
van Zeijl CJ; Fliers E; van Koppen CJ; Surovtseva OV; de Gooyer ME; Mourits MP; Wiersinga WM; Miltenburg AM; Boelen A
Thyroid; 2011 Feb; 21(2):169-76. PubMed ID: 20954819
[TBL] [Abstract][Full Text] [Related]
23. Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves' disease.
Tsui S; Naik V; Hoa N; Hwang CJ; Afifiyan NF; Sinha Hikim A; Gianoukakis AG; Douglas RS; Smith TJ
J Immunol; 2008 Sep; 181(6):4397-405. PubMed ID: 18768899
[TBL] [Abstract][Full Text] [Related]
24. Complete inhibition of rhTSH-, Graves' disease IgG-, and M22-induced cAMP production in differentiated orbital fibroblasts by a low-molecular-weight TSHR antagonist.
van Zeijl CJ; van Koppen CJ; Surovtseva OV; de Gooyer ME; Plate R; Conti P; Karstens WJ; Timmers M; Saeed P; Wiersinga WM; Miltenburg AM; Fliers E; Boelen A
J Clin Endocrinol Metab; 2012 May; 97(5):E781-5. PubMed ID: 22419705
[TBL] [Abstract][Full Text] [Related]
25. Inhibitory Effect of Idelalisib, a Selective Phosphatidylinositol 3-Kinase δ Inhibitor, on Adipogenesis in an In Vitro Model of Graves' Orbitopathy.
Ko J; Kim JY; Lee EJ; Yoon JS
Invest Ophthalmol Vis Sci; 2018 Sep; 59(11):4477-4485. PubMed ID: 30193323
[TBL] [Abstract][Full Text] [Related]
26. TSH-Mediated TNFα Production in Human Fibrocytes Is Inhibited by Teprotumumab, an IGF-1R Antagonist.
Chen H; Shan SJ; Mester T; Wei YH; Douglas RS
PLoS One; 2015; 10(6):e0130322. PubMed ID: 26087256
[TBL] [Abstract][Full Text] [Related]
27. Current Insights into the Pathogenesis of Graves' Ophthalmopathy.
Bahn RS
Horm Metab Res; 2015 Sep; 47(10):773-8. PubMed ID: 26361262
[TBL] [Abstract][Full Text] [Related]
28. Cytokines as Targets of Novel Therapies for Graves' Ophthalmopathy.
Fallahi P; Ferrari SM; Elia G; Ragusa F; Paparo SR; Patrizio A; Camastra S; Miccoli M; Cavallini G; Benvenga S; Antonelli A
Front Endocrinol (Lausanne); 2021; 12():654473. PubMed ID: 33935970
[TBL] [Abstract][Full Text] [Related]
29. Evidence for enhanced Thy-1 (CD90) expression in orbital fibroblasts of patients with Graves' ophthalmopathy.
Khoo TK; Coenen MJ; Schiefer AR; Kumar S; Bahn RS
Thyroid; 2008 Dec; 18(12):1291-6. PubMed ID: 18976167
[TBL] [Abstract][Full Text] [Related]
30. A review of TSHR- and IGF-1R-related pathogenesis and treatment of Graves' orbitopathy.
Cui X; Wang F; Liu C
Front Immunol; 2023; 14():1062045. PubMed ID: 36742308
[TBL] [Abstract][Full Text] [Related]
31. Pentraxin-3 Is a TSH-Inducible Protein in Human Fibrocytes and Orbital Fibroblasts.
Wang H; Atkins SJ; Fernando R; Wei RL; Smith TJ
Endocrinology; 2015 Nov; 156(11):4336-44. PubMed ID: 26287404
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of TSH/IGF-1 Receptor Crosstalk by Teprotumumab as a Treatment Modality of Thyroid Eye Disease.
Krieger CC; Sui X; Kahaly GJ; Neumann S; Gershengorn MC
J Clin Endocrinol Metab; 2022 Mar; 107(4):e1653-e1660. PubMed ID: 34788857
[TBL] [Abstract][Full Text] [Related]
33. Insulin and insulin-like growth factor-1 can modulate the phosphoinositide-3-kinase/Akt/FoxO1 pathway in SZ95 sebocytes in vitro.
Mirdamadi Y; Thielitz A; Wiede A; Goihl A; Papakonstantinou E; Hartig R; Zouboulis CC; Reinhold D; Simeoni L; Bommhardt U; Quist S; Gollnick H
Mol Cell Endocrinol; 2015 Nov; 415():32-44. PubMed ID: 26257240
[TBL] [Abstract][Full Text] [Related]
34. Thyrotropin receptor expression in cultured Graves' orbital preadipocyte fibroblasts is stimulated by thyrotropin.
Bahn RS; Dutton CM; Joba W; Heufelder AE
Thyroid; 1998 Feb; 8(2):193-6. PubMed ID: 9510130
[TBL] [Abstract][Full Text] [Related]
35. Pathogenesis of Graves' ophthalmopathy: the role of autoantibodies.
Khoo TK; Bahn RS
Thyroid; 2007 Oct; 17(10):1013-8. PubMed ID: 17935483
[TBL] [Abstract][Full Text] [Related]
36. Possible targets for nonimmunosuppressive therapy of Graves' orbitopathy.
Zhang L; Grennan-Jones F; Draman MS; Lane C; Morris D; Dayan CM; Tee AR; Ludgate M
J Clin Endocrinol Metab; 2014 Jul; 99(7):E1183-90. PubMed ID: 24758182
[TBL] [Abstract][Full Text] [Related]
37. Thyrotropin Receptor Antagonism by a Novel Small Molecule: Preclinical
Kahaly GJ; Steiner L; van der Lee MMC; van Achterberg TAE; Arends RJ; Karstens WFJ; Weirauch T; Henseling J; Frommer L; Wolf J; George A
Thyroid; 2023 Jun; 33(6):732-742. PubMed ID: 37016815
[No Abstract] [Full Text] [Related]
38. Expression of Endogenous Putative TSH Binding Protein in Orbit.
Draman MS; Grennan-Jones F; Taylor P; Muller I; Evans S; Haridas A; Morris DS; Rees DA; Lane C; Dayan C; Zhang L; Ludgate M
Curr Issues Mol Biol; 2021 Oct; 43(3):1794-1804. PubMed ID: 34889904
[TBL] [Abstract][Full Text] [Related]
39. TSH receptor transcripts and TSH receptor-like immunoreactivity in orbital and pretibial fibroblasts of patients with Graves' ophthalmopathy and pretibial myxedema.
Stadlmayr W; Spitzweg C; Bichlmair AM; Heufelder AE
Thyroid; 1997 Feb; 7(1):3-12. PubMed ID: 9086563
[TBL] [Abstract][Full Text] [Related]
40. Platelet-Derived Growth Factor-BB Enhances Adipogenesis in Orbital Fibroblasts.
Virakul S; Dalm VA; Paridaens D; van den Bosch WA; Mulder MT; Hirankarn N; van Hagen PM; Dik WA
Invest Ophthalmol Vis Sci; 2015 Aug; 56(9):5457-64. PubMed ID: 26284551
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
